- Conditions
- Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug, Adverse Drug Event
- Interventions
- FLUAD®, Fluzone® High-Dose
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 757 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pneumococcal Infections
- Interventions
- Tetanus-diphtheria toxoids (Td), 7-valent pneumococcal conjugate vaccine, 23-valent polysaccharide vaccine
- Biological
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
- Interventions
- FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Durham, North Carolina
- Conditions
- Japanese Encephalitis
- Interventions
- Japanese Encephalitis Virus vaccine, inactivated, adsorbed
- Biological
- Lead sponsor
- Valneva Austria GmbH
- Industry
- Eligibility
- 17 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Alexandria, Virginia
- Conditions
- Pain, Injection Site Reaction, Adverse Drug Event
- Interventions
- Observational
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 5 Years to 15 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Oakland, California • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
- Interventions
- mRNA COVID-19, IIV4, Placebo (saline)
- Biological · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 348 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio
- Conditions
- Safety, Adverse Event Following Immunisation, Birth Outcomes
- Interventions
- Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccine
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 384 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Cincinnati, Ohio
- Conditions
- Fever, Adverse Event Following Immunisation
- Interventions
- Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Weeks to 30 Weeks
- Enrollment
- 524 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Oakland, California • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- Birth Outcomes, Safety, Adverse Event Following Immunization
- Interventions
- mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine)
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 2 more